Literature DB >> 25253466

Intrahepatic cholangiocarcinoma and cholangiolocellular carcinoma in cirrhosis and chronic viral hepatitis.

Shun-ichi Ariizumi1, Masakazu Yamamoto.   

Abstract

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer. Cirrhosis and chronic viral hepatitis are known to be important risk factors for ICC, especially the mass-forming (MF) type of ICC at the periphery of the liver. Cholangiolocellular carcinoma (CoCC) is a rare type of primary liver cancer, which is thought to originate from hepatic progenitor or stem cells. CoCC often exhibits the similar MF type at the periphery of the liver, as ICC, and CoCC is also associated with cirrhosis or chronic viral hepatitis. Better survival rates after surgery have been reported for ICC patients with chronic viral hepatitis than for those without chronic viral hepatitis, although survival rates did not differ significantly in relation to cirrhosis. On the other hand, patients with CoCC had better surgical results than those with MF-type ICC. This review summarizes the clinical characteristics and surgical outcomes of ICC and CoCC associated with cirrhosis or chronic viral hepatitis.

Entities:  

Mesh:

Year:  2014        PMID: 25253466     DOI: 10.1007/s00595-014-1031-0

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  75 in total

1.  Survival outcomes and prognostic factors of surgical therapy for all potentially resectable intrahepatic cholangiocarcinoma: a large single-center cohort study.

Authors:  Xianwu Luo; Lei Yuan; Yi Wang; Ruiliang Ge; Yanfu Sun; Gongtian Wei
Journal:  J Gastrointest Surg       Date:  2014-01-07       Impact factor: 3.452

2.  Combined hepatocellular-cholangiocarcinoma had poor outcomes after hepatectomy regardless of Allen and Lisa class or the predominance of intrahepatic cholangiocarcinoma cells within the tumor.

Authors:  Shun-Ichi Ariizumi; Yoshihito Kotera; Satoshi Katagiri; Masayuki Nakano; Masakazu Yamamoto
Journal:  Ann Surg Oncol       Date:  2011-11-24       Impact factor: 5.344

3.  Hepatitis B virus infection: a favorable prognostic factor for intrahepatic cholangiocarcinoma after resection.

Authors:  Hua-Bang Zhou; Hui Wang; Yu-Qiong Li; Shuang-Xi Li; Hao Wang; Dong-Xun Zhou; Qian-Qian Tu; Qing Wang; Shan-Shan Zou; Meng-Chao Wu; He-Ping Hu
Journal:  World J Gastroenterol       Date:  2011-03-14       Impact factor: 5.742

4.  Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound.

Authors:  Ramón Vilana; Alejandro Forner; Luis Bianchi; Angeles García-Criado; Jordi Rimola; Carlos Rodríguez de Lope; María Reig; Carmen Ayuso; Concepció Brú; Jordi Bruix
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

5.  Prognostic value of cirrhosis for intrahepatic cholangiocarcinoma after surgical treatment.

Authors:  Ya-yong Li; Hao Li; Pin Lv; Gang Liu; Xiao-rong Li; Bu-ning Tian; Dao-jin Chen
Journal:  J Gastrointest Surg       Date:  2011-01-19       Impact factor: 3.452

Review 6.  Intrahepatic cholangiocarcinoma: macroscopic type and stage classification.

Authors:  Susumu Yamasaki
Journal:  J Hepatobiliary Pancreat Surg       Date:  2003

7.  Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential.

Authors:  U Broomé; R Löfberg; B Veress; L S Eriksson
Journal:  Hepatology       Date:  1995-11       Impact factor: 17.425

Review 8.  Epidemiology of cholangiocarcinoma: an update focusing on risk factors.

Authors:  Hai-Rim Shin; Jin-Kyoung Oh; Eric Masuyer; Maria-Paula Curado; Veronique Bouvard; Yue-Yi Fang; Surapon Wiangnon; Banchob Sripa; Sung-Tae Hong
Journal:  Cancer Sci       Date:  2009-12-04       Impact factor: 6.716

9.  Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans.

Authors:  Hashem B El-Serag; Eric A Engels; Ola Landgren; Elizabeth Chiao; Louise Henderson; Harshinie C Amaratunge; Thomas P Giordano
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

10.  Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.

Authors:  Tania M Welzel; Barry I Graubard; Hashem B El-Serag; Yasser H Shaib; Ann W Hsing; Jessica A Davila; Katherine A McGlynn
Journal:  Clin Gastroenterol Hepatol       Date:  2007-08-06       Impact factor: 11.382

View more
  10 in total

1.  Low Incidence of Lymph Node Metastasis After Resection of Hepatitis Virus-Related Intrahepatic Cholangiocarcinoma.

Authors:  Hiroya Iida; Masaki Kaibori; Shogo Tanaka; Shigekazu Takemura; Hiroshi Wada; Fumitoshi Hirokawa; Takuya Nakai; Michihiro Hayashi; Hidetoshi Eguchi; Shoji Kubo
Journal:  World J Surg       Date:  2017-04       Impact factor: 3.352

2.  GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma.

Authors:  Sonia Brun; Firas Bassissi; Cindy Serdjebi; Marie Novello; Jennifer Tracz; François Autelitano; Marie Guillemot; Philippe Fabre; Jérôme Courcambeck; Christelle Ansaldi; Eric Raymond; Philipe Halfon
Journal:  Invest New Drugs       Date:  2019-02-19       Impact factor: 3.850

3.  Intrahepatic Cholangiocarcinoma With Neither Intrahepatic Metastasis Nor Lymph Node Metastasis Is the Optimal Indication for Hepatectomy With Adjuvant Therapy.

Authors:  Shun-Ichi Ariizumi; Masakazu Yamamoto; Yoshihito Kotera; Ryota Higuchi; Shingo Yamashita; Takaaki Kato; Yoshihiro Hirata; Satoshi Katagiri; Goro Honda; Hiroto Egawa
Journal:  Cancer Diagn Progn       Date:  2022-03-03

4.  Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis.

Authors:  Francesco Tovoli; Pietro Guerra; Massimo Iavarone; Letizia Veronese; Matteo Renzulli; Stefania De Lorenzo; Francesca Benevento; Giovanni Brandi; Federico Stefanini; Fabio Piscaglia
Journal:  Liver Cancer       Date:  2020-10-28       Impact factor: 11.740

Review 5.  Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.

Authors:  Alphonse E Sirica; Mario Strazzabosco; Massimiliano Cadamuro
Journal:  Adv Cancer Res       Date:  2020-12-09       Impact factor: 6.242

6.  Intrahepatic cholangiocarcinoma prognostic determination using pre-operative serum C-reactive protein levels.

Authors:  Zi-Ying Lin; Zhen-Xing Liang; Pei-Lin Zhuang; Jie-Wei Chen; Yun Cao; Li-Xu Yan; Jing-Ping Yun; Dan Xie; Mu-Yan Cai
Journal:  BMC Cancer       Date:  2016-10-12       Impact factor: 4.430

7.  Small cholangiolocellular carcinoma that was difficult to distinguish from cholangiocellular carcinoma: a case report.

Authors:  Norihiro Ishii; Kenichiro Araki; Takahiro Yamanaka; Tadashi Handa; Mariko Tsukagoshi; Takamichi Igarashi; Akira Watanabe; Norio Kubo; Shinichi Aishima; Hiroyuki Kuwano; Ken Shirabe
Journal:  Surg Case Rep       Date:  2017-09-15

8.  Impact of cirrhosis on long-term survival outcomes of patients with intrahepatic cholangiocarcinoma.

Authors:  Jian Wang; Yiwen Qiu; Yi Yang; Shu Shen; Ming Zhi; Bo Zhang; Wentao Wang
Journal:  Cancer Med       Date:  2022-04-12       Impact factor: 4.711

9.  Intrahepatic cholangiocarcinoma in a patient with Wilson's disease: a case report.

Authors:  Yosuke Mukai; Hiroshi Wada; Hidetoshi Eguchi; Daisaku Yamada; Tadafumi Asaoka; Takehiro Noda; Koichi Kawamoto; Kunihito Gotoh; Yutaka Takeda; Masahiro Tanemura; Koji Umeshita; Yumiko Hori; Eiichi Morii; Yuichiro Doki; Masaki Mori
Journal:  Surg Case Rep       Date:  2016-03-23

10.  Hot topics in cholangiocarcinoma.

Authors:  Giovanni Brandi
Journal:  Transl Cancer Res       Date:  2019-04       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.